AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02922699
Drug: OMEZ 40
RxNorm normalized name: Omeza
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omez 40 given to patients for 58days along with Amoxicilin and Clarithromycin
Trial: NCT02922699
Drug: OMEZ 80
RxNorm normalized name: Omeza
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omez 80 patients for 58days along with Amoxicilin and Clarithromycin
Trial: NCT04093024
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule
Trial: NCT00488306
Drug: tigecycline
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04298008
Drug: AZD6738
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD6738 (240 ) mg bid on D15-D28 Every 4 weeks
Trial: NCT03390842
Drug: TRC101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral suspension
Trial: NCT03390842
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral suspension
Trial: NCT02605057
Drug: LEO 80185 gel
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04384692
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04384692
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03373903
Drug: BEZ235
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00335179
Drug: Vehicle cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle cream in 250 mg
Trial: NCT04185025
Drug: Ceramides
RxNorm normalized name: GLYCOCERAMIDES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On the 0th day, it is determined that one of the leg extensions of the participant is the test side using CeraVe Moisturising Lotion and the opposite side is the control side using Half Mu ceramide body milk by the random table. Participants are required to use the product in the morning and evening according to the Product Use Procedures, during which other moisturizing products or emollients are prohibited. And the follow-up tests are conducted at the prescribed time. At each visit, empty packaging of products used during this period must be collected; if they are not used up as required, the remaining products must be collected.
Trial: NCT03055286
Drug: CWP232291
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For cohort 1-3, a fixed dose of ara-C at 1 G/m2 will be administered IV over 2 hours daily from Day 1 to Day 5 following CWP232291 infusion.~For cohort 4, a fixed dose of ara-C at 1 G/m2 will be administered IV over 2 hours daily from Day 1 to Day 7 following 250 mg/m2 CWP232291 infusion.
Trial: NCT03920644
Drug: Placebo Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Patch, 1 patch behind the ear.
Trial: NCT03920644
Drug: Placebo Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Gel,up to 6 administration of intranasal gel.
Trial: NCT03439488
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo as oral tablets will be administered in Parts 1, 2 and 3.
Trial: NCT01584544
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral pills, 1000mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
Trial: NCT01584544
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral pills, 1200mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
Trial: NCT01584544
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral pills, 1350mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
Trial: NCT01584544
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral pills, 1500mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
Trial: NCT01584544
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral pills, 1650mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
Trial: NCT00318409
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01078818
Drug: Oral and intravenous Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative Period:1oral placebo/24h Postoperative Period:200cc physiologic solution iv placebo /24-48h x 3 dosis + 1oral placebo/24h One month Follow-up:1 oral placebo/24h
Trial: NCT03577431
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 40 mg/kg administered intravenously (IV) within 24 to 72 hours prior to Treg product (arTreg-CSB) infusion.
Trial: NCT01060007
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01060007
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00081978
Drug: TMC125
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01654211
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single iv infusion
Trial: NCT00858611
Drug: Flulaval (Registered) Seasonal Influenza Vaccine
RxNorm normalized name: Flulaval 2024-2025
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03165253
Drug: Bifidobacterium Animalis Oral Product
RxNorm normalized name: Bifidobacterium animalis Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The synbiotic group will receive this product.
Trial: NCT03165253
Drug: Clarithromycin Oral Tablet
RxNorm normalized name: clarithromycin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg/day B.I.D.
Trial: NCT00417820
Drug: BCT194
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01394120
Drug: Targeted Therapy Tailored Treatment
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted therapy tailored treatment, based on molecular determination in pancreas cancer specimen~* Tim Synthase (TS) (neg), ERCC-1 (neg), Topoisomerase I (Topo I) (pos) : FOLFIRINOX~* TS (neg), ERCC-1 (neg), Topo I (neg): FOLFOX~* TS (neg), ERCC-1 (pos), Topo I (pos): FOLFIRI~* TS (neg), ERCC-1 (pos), Topo I (neg): Capecitabine/Gemcitabine~* TS (pos), EGFR Not Amplificate, K-Ras Mutation (pos) : Gemcitabine single agent~* TS (pos), EGFR Ampl or K-Ras mut (neg): Gemcitabine plus Erlotinib
Trial: NCT01394120
Drug: Standard Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients treated based on investigator´s criteria: : FOLFIRINOX, FOLFOX, FOLFIRI, Capecitabine-Gemcitabine, Erlotinib-Gemcitabine or Gemcitabine single agent
Trial: NCT01036594
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone 20mg po qam and 10mg po qpm~If participant has ≥30% PSA decline at 12 week evaluation, treatment continues until progressive disease (by RECIST criteria OR by PSAWG criteria) is documented. After that, drug will be discontinued. If participant has \<30% PSA decline, patient goes off study.
Trial: NCT01291186
Drug: BPV6NO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intrathecal bupivacaine 6 mg for BMI less than 27.5 kg/m2
Trial: NCT04308174
Drug: Gem/Cis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant Gemcitabine/Cisplatin
Trial: NCT01291186
Drug: BPV7NO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intrathecal bupivacaine 7 mg for BMI less than 27.5 kg/m2
Trial: NCT01291186
Drug: BPV8NO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intrathecal bupivacaine 8 mg for BMI less than 27.5 kg/m2
Trial: NCT01291186
Drug: BPV9NO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intrathecal bupivacaine 9 mg for BMI less than 27.5 kg/m2
Trial: NCT01291186
Drug: BPV10NO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intrathecal bupivacaine 10 mg for BMI less than 27.5 kg/m2
Trial: NCT01291186
Drug: BPV11NO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intrathecal bupivacaine 11 mg for BMI less than 27.5 kg/m2
Trial: NCT01291186
Drug: BPV10O
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intrathecal bupivacaine 10 mg for BMI over 27.5 kg/m2
Trial: NCT01291186
Drug: BPV11O
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intrathecal bupivacaine 11 mg for BMI over 27.5 kg/m2
Trial: NCT02215434
Drug: Testosterone, Transdermal, Behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 0.5% testosterone Biolipid/B2
Trial: NCT03661879
Drug: NNC9204-1706
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive NNC9204-1706 subcutaneous (s.c., under the skin) injection(s) once daily (OD) for 10 weeks. They will either receive the same dose throughout the trial, or the dose will be escalated over a period of 1-3 weeks and continued for at least 7 weeks at the same dose.
Trial: NCT03661879
Drug: Placebo (NNC9204-1706)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo (NNC9204-1706) s.c., injection(s) OD for 10 weeks.
Trial: NCT03131648
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo contains the same excipients, in the same concentration only lacking tralokinumab
Trial: NCT03359473
Drug: GSK2881078
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2881078 will be available as capsules for oral administration. GSK2881078 will be administered once daily by the oral route at a dose of 1 mg and 2mg to post-menopausal female subjects and male subjects, respectively.
Trial: NCT03359473
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be administered two capsules of GSK2881078 matching placebo once daily by the oral route.
Trial: NCT00568516
Drug: ASP3550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous administration
Trial: NCT04653467
Drug: GLPG4399 oral suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG4399 for oral administration
Trial: NCT04653467
Drug: GLPG4399 capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG4399 for oral administration
Trial: NCT04653467
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral suspension
Trial: NCT00740610
Drug: GS-9450 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match GS-9450 administered orally once daily
Trial: NCT01610284
Drug: BKM120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BKM120 100 mg once daily
Trial: NCT01610284
Drug: BKM120 matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BKM120 matching placebo, once daily
Trial: NCT00206232
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Research subjects are randomized to placebo versus spironolactone 25mg daily and followed for 6 months.
Trial: NCT04554056
Drug: PEG-rhG-CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEGylated Recombinant Human Granulocyte Colony-Stimulating Factor
Trial: NCT00484744
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00484744
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02816567
Drug: placebo - isotonic saline serum
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02816567
Drug: sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01287182
Drug: Ateronon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ateronon daily for 3 months
Trial: NCT02854722
Drug: Deferasirox and calcium-vitamin D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: deferasirox and calcium-vitamin D3 Deferasirox is an orodispersible tablet and should be taken daily 30 minutes before breakfast, with a dose of 10 mg/Kg/day ± 5 mg/Kg/day during 12 month.~Calcium 500 mg and vitamin D3 800 IU should also be taken daily as a basic therapy.
Trial: NCT02854722
Drug: Calcium-vitamin D3
RxNorm normalized name: Calcium/Cholecalciferol 600 MG-5 MCG Oral Capsule, Liquid Filled [CALCIUM-VITAMIN D3]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium 500 mg and vitamin D3 800 IU are taken daily as a basic therapy.
Trial: NCT01508923
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mcg/kg injected subcutaneously daily in each treatment period in random order. In total, subjects are treated 9-10 days
Trial: NCT02536404
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01125358
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally, twice daily for up to 7 weeks of treatment
Trial: NCT04332835
Drug: Standard Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy defined by institutional protocol.
Trial: NCT04311359
Drug: Drugs, Generic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All drugs having 19 or more Brain Oedema cases reported to the FAERS database
Trial: NCT00956709
Drug: levobupivacaïne 0,5 %
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mL de levobupivacaïne 0,5 % 20mL de ropivacaïne 0,5 %
Trial: NCT00956709
Drug: ropivacaïne 0,5 %
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mL de ropivacaïne 0,5 %
Trial: NCT00693056
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (w/o API)
Trial: NCT00693056
Drug: RX-10100 10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/dose of RX-10100
Trial: NCT01762020
Drug: Standard Preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard creams
Trial: NCT01587898
Drug: GSK1278863
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT00578760
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OD for course of cisplatin chemotherapy
Trial: NCT04134260
Drug: Hormone Therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receive hormone therapy
Trial: NCT04059900
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The medication was applied daily p.o. from day 0 to day 28. The dosage was 20 drops three times daily before the meals
Trial: NCT02282241
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02080273
Drug: Colgate Total toothpaste
RxNorm normalized name: Colgate Total Toothpaste Whitening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.32% sodium fluoride (1450 ppm NaF) and 0.3% triclosan. Colgate Total toothpaste is the active comparator toothpaste
Trial: NCT02080273
Drug: Parodontax toothpaste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1400 ppm sodium fluoride (NaF), Parodontax toothpaste is the active comparator toothpaste
Trial: NCT00119678
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable, intravenous, 0 mg, every 28 days, 12 months
Trial: NCT02496780
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once or 3x daily
Trial: NCT03376321
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo matching to pimodivir, orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of placebo on Day 1 \[evening\], dosing will continue until the morning of Day 6). Participants who meet treatment extension criteria may receive an additional 5 day course of the same treatment as received at study start (on Days 6 through 10).
Trial: NCT00313781
Drug: CP-751,871
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-750,871 is administered intravenously at a dose of 20 mg/kg on day 1 of each 21-day cycle (for patient convenience and logistical management, the dose of CP-751,871 may be deferred up to 7 days).
Trial: NCT01842516
Drug: LCB01-0371 800mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCB0-0371 800mg
Trial: NCT01842516
Drug: LCB01-0371 1200mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCB01-0371 1200mg
Trial: NCT01842516
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00329758
Drug: rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 mg oral, during 10 days
Trial: NCT04139993
Drug: Microbiota-based Formulation RBX7455
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00329758
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00744302
Drug: physiological (1.25 mmol/L ) calcium dialysate
RxNorm normalized name: DIALYSATE,DUOSOL BICARBONATE 25 W/O CALCIUM SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Using the physiological calcium dialysate (1.25 mmol/L calcium dialysate)for Stable haemodialysis treatment for more than 3 months, undergoing 2 to 3 times haemodialysis a week for 4 to 5 hours per session
Trial: NCT00154323
Drug: Oxcarbazepine
RxNorm normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02537288
Drug: Placebo (for fedovapagon)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00877123
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: similar placebo once a month for three consecutive months
Trial: NCT05504967
Drug: Oradexon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: With a syringe aspirate 2.5 ml of a 5mg/ml dexamethasone solution, for a total of 12.5mg. Repeat the procedure with another syringe. 2 syringes must be prepared, one for each of the tonsil sites.
Trial: NCT00924573
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT02113397
Drug: TOBI™ Podhaler™ 112 mg inhaled twice daily
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02578043
Drug: Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% (Taro Pharmaceuticals Inc.)
Trial: NCT02578043
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (vehicle of the test product) (Taro Pharmaceuticals Inc.)
Trial: NCT01347983
Drug: Tocilizumab+Methotrexate(MTX)
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab: 8 mg/kg every 4 weeks, IV infusion Methotrexate: 10-20 mg/week
Trial: NCT02834754
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Currently there are no clinical guidelines and no standard of care for the maintenance of surgically induced remission. There are no medications that have consistently been proven to be efficacious at preventing recurrent Crohn's disease and as such, no active equivalent arm is being used. Due to the lack of effective prophylactic therapy, many physicians and patients opt not to initiate medical therapy after surgery, rather wait until Crohn's disease recurs, or wait to perform a post-operative colonoscopy within 6-12 months of surgery, and decide on initiating Crohn's disease therapy based on endoscopic Rutgeerts; score. Therefore, acknowledging that many patients are not administered post-operative maintenance medications, we feel the placebo arm is justified.
Trial: NCT01809639
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard placebo
Trial: NCT03836001
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo is a tablet that looks like a drug but has no drug or other active ingredient in it.
Trial: NCT00392379
Drug: Placebo lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo lozenge
Trial: NCT02971033
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants assigned to this intervention will receive placebo every day for 12 weeks
Trial: NCT02060916
Drug: PAZ320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-center pilot study, open label dose escalation design
Trial: NCT01765010
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04564638
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04269031
Drug: AZD2373 subcutaneous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomised subjects will receive a single ascending dose of AZD2373 by SC injection (dose 1, dose 2, dose 3, dose 4, dose 5 and dose 6).
Trial: NCT04269031
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomised subjects will receive a single ascending dose of placebo (saline solution) by SC injection.
Trial: NCT03252015
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01273584
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo maximum dosage 2 tablets 3 times a day ( with meals) start with 1 tablet twice a day and gradually titrate upwards to maximum dose
Trial: NCT00158132
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pills
Trial: NCT01543581
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no